CN109198353A - 一种镇痛安神固体饮料及其制备方法 - Google Patents
一种镇痛安神固体饮料及其制备方法 Download PDFInfo
- Publication number
- CN109198353A CN109198353A CN201811115455.2A CN201811115455A CN109198353A CN 109198353 A CN109198353 A CN 109198353A CN 201811115455 A CN201811115455 A CN 201811115455A CN 109198353 A CN109198353 A CN 109198353A
- Authority
- CN
- China
- Prior art keywords
- parts
- solid beverage
- pain
- sedative
- analgesic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007787 solid Substances 0.000 title claims abstract description 44
- 230000000202 analgesic effect Effects 0.000 title claims abstract description 43
- 235000013361 beverage Nutrition 0.000 title claims abstract description 43
- 239000000932 sedative agent Substances 0.000 title claims abstract description 42
- 230000001624 sedative effect Effects 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 52
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 33
- 239000000843 powder Substances 0.000 claims abstract description 29
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 24
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 23
- 244000062730 Melissa officinalis Species 0.000 claims abstract description 23
- 235000010654 Melissa officinalis Nutrition 0.000 claims abstract description 23
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 23
- 239000000865 liniment Substances 0.000 claims abstract description 23
- 235000013976 turmeric Nutrition 0.000 claims abstract description 23
- 239000001556 apium graveolens l. seed extract Substances 0.000 claims abstract description 21
- 229940116732 celery seed extract Drugs 0.000 claims abstract description 21
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000000796 flavoring agent Substances 0.000 claims abstract description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 38
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 28
- 229920001202 Inulin Polymers 0.000 claims description 19
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 19
- 229940029339 inulin Drugs 0.000 claims description 19
- 235000010355 mannitol Nutrition 0.000 claims description 19
- 229940088594 vitamin Drugs 0.000 claims description 15
- 239000011782 vitamin Substances 0.000 claims description 15
- 229930003427 Vitamin E Natural products 0.000 claims description 14
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 14
- 235000019165 vitamin E Nutrition 0.000 claims description 14
- 229940046009 vitamin E Drugs 0.000 claims description 14
- 239000011709 vitamin E Substances 0.000 claims description 14
- 239000011691 vitamin B1 Substances 0.000 claims description 13
- 239000003381 stabilizer Substances 0.000 claims description 10
- 229920002752 Konjac Polymers 0.000 claims description 9
- 235000013355 food flavoring agent Nutrition 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 9
- 235000005979 Citrus limon Nutrition 0.000 claims description 7
- 244000131522 Citrus pyriformis Species 0.000 claims description 7
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 claims description 7
- 239000013078 crystal Substances 0.000 claims description 7
- 235000013399 edible fruits Nutrition 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- 229930091371 Fructose Natural products 0.000 claims 1
- 240000008866 Ziziphus nummularia Species 0.000 claims 1
- 235000011194 food seasoning agent Nutrition 0.000 claims 1
- 229960002737 fructose Drugs 0.000 claims 1
- 208000002193 Pain Diseases 0.000 abstract description 34
- 230000036407 pain Effects 0.000 abstract description 34
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 11
- 210000004556 brain Anatomy 0.000 abstract description 11
- 206010022437 insomnia Diseases 0.000 abstract description 11
- 241000894006 Bacteria Species 0.000 abstract description 9
- 210000000936 intestine Anatomy 0.000 abstract description 7
- 210000005036 nerve Anatomy 0.000 abstract description 6
- 235000013406 prebiotics Nutrition 0.000 abstract description 6
- 206010065390 Inflammatory pain Diseases 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 4
- 239000004615 ingredient Substances 0.000 abstract description 4
- 230000002906 microbiologic effect Effects 0.000 abstract description 3
- 235000019634 flavors Nutrition 0.000 abstract description 2
- 239000012535 impurity Substances 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000000725 suspension Substances 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 15
- 239000003814 drug Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 239000000284 extract Substances 0.000 description 8
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 7
- 240000007087 Apium graveolens Species 0.000 description 6
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 6
- 235000010591 Appio Nutrition 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 235000013311 vegetables Nutrition 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 4
- 102000000584 Calmodulin Human genes 0.000 description 4
- 108010041952 Calmodulin Proteins 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 210000001320 hippocampus Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229940118199 levulan Drugs 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 3
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 3
- 230000000049 anti-anxiety effect Effects 0.000 description 3
- 239000002249 anxiolytic agent Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000012754 curcumin Nutrition 0.000 description 3
- 229940109262 curcumin Drugs 0.000 description 3
- 239000004148 curcumin Substances 0.000 description 3
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 3
- 230000004968 inflammatory condition Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- -1 oligofructose Chemical compound 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
- SMRPGWBDLOQHOS-UHFFFAOYSA-N 5-[4,5-dihydroxy-6-(hydroxymethyl)-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxy-3,4-dihydroxy-6-[[9-hydroxy-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]oxane-2-carboxylic acid Chemical compound OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(C(O)C2O)C(O)=O)OC2C(C3C(C4C(C5(CCC6(C)C(O)CC(C)(C)CC6C5=CC4=O)C)(C)CC3)(C)CC2)(C)CO)OC(CO)C(O)C1O SMRPGWBDLOQHOS-UHFFFAOYSA-N 0.000 description 2
- HJXMNVQARNZTEE-UHFFFAOYSA-N Butylphthalide Chemical compound C1=CC=C2C(CCCC)OC(=O)C2=C1 HJXMNVQARNZTEE-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000000146 antalgic effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000005171 mammalian brain Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 210000002442 prefrontal cortex Anatomy 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- PPRSVUXPYPBULA-UHFFFAOYSA-N saponin A Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6=O)C(C)(C)C5CCC34C)C2C1)C(=O)O PPRSVUXPYPBULA-UHFFFAOYSA-N 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 208000022925 sleep disturbance Diseases 0.000 description 2
- 108010050939 thrombocytin Proteins 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- FLDFNEBHEXLZRX-DLQNOBSRSA-N Nystose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(O[C@@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FLDFNEBHEXLZRX-DLQNOBSRSA-N 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960000212 aminophenazone Drugs 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 229950005197 butylphthalide Drugs 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000001362 electron spin resonance spectrum Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000007184 endocrine pathway Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000105 enteric nervous system Anatomy 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000003694 hair properties Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000008088 immune pathway Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000002584 ketoses Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- FLDFNEBHEXLZRX-UHFFFAOYSA-N nystose Natural products OC1C(O)C(CO)OC1(CO)OCC1(OCC2(OC3C(C(O)C(O)C(CO)O3)O)C(C(O)C(CO)O2)O)C(O)C(O)C(CO)O1 FLDFNEBHEXLZRX-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229960001475 zolpidem Drugs 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Anesthesiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种镇痛安神固体饮料及其制备方法，该镇痛安神固体饮料为深黄色，呈均匀粉末状，具有本品特有的气味、滋味，无异味，无肉眼可见外来杂质，冲溶后呈均匀的悬浮液，其理化指标和微生物指标等均符合标准要求，对疼痛、失眠人群有效率达90％以上，先采用芹菜籽提取物、姜黄成分改善炎症疼痛，再采用酸枣仁粉、香蜂草、γ‑氨基丁酸改善因疼痛造成的神经方面问题，最后采用复合益生元改善肠道益生菌，通过脑肠轴体系，调节身体免疫的同时改善疼痛引起的神经问题；其制备方法简单，生产成本低，易操作实施。
Description
技术领域
本发明涉及食品加工技术领域，具体涉及一种镇痛安神固体饮料及其制备方法。
背景技术
疼痛是许多身体状况中主要的症状，并会显著影响人的生活质量和一般功能。疼痛的范围从轻度的不适或隐约的痛苦至急性的常难以忍受的痛苦，并且可以是泛发性的或局部的。对于治疗疼痛和睡眠障碍有各种可用的药物和制剂。NSAID(非甾体抗炎药)例如阿司匹林、布洛芬和萘普生，是其中最频繁使用的处方，和在急性和慢性炎性病状导致的疼痛中用于缓解症状的非处方药。但是患者仍面临它们严重并发症(如胃肠道(GI)和肾的副作用等)。
失眠或睡不着，由压力或其他病因导致的睡眠障碍是普遍流行的，并影响大约30％的普通人群。现今长期受限的睡眠已变为我们社会广泛而严重的问题。失眠损害认知和身体功能，并与范围广泛的受损日间功能相关，跨越许多情感、社会和身体领域，并可导致其他障碍和健康风险。目前，对于失眠的一线治疗为抗组胺剂，苯并二氮类和非苯并二氮类。这些药物具有各种有害影响，例如用于失眠的药物是上瘾性的，因此对患者有害。更新的睡眠诱导药物包括唑吡坦，其也显示许多副作用，最严重的为嗜睡、反弹性失眠、依赖和滥用。
因此，采用药物缓解疼痛、失眠等症状都或多或少的具有一定的毒副作用，会产生药物依耐性，药物反弹等问题，不利于人体健康，因此，急需开发一种能快速缓解疼痛、失眠等症状的食品，且依耐性小，安全可靠，无毒副作用。
发明内容
针对现有技术中存在的问题，本发明的目的在于提供一种镇痛安神固体饮料及其制备方法，该镇痛安神固体饮料为深黄色，呈均匀粉末状，具有本品特有的气味、滋味，无异味，无肉眼可见外来杂质，冲溶后呈均匀的悬浮液，其理化指标和微生物指标等均符合标准要求，对疼痛、失眠人群有效率达90％以上，先采用芹菜籽提取物、姜黄成分改善炎症疼痛，再采用酸枣仁粉、香蜂草、γ-氨基丁酸改善因疼痛造成的神经方面问题，最后采用复合益生元改善肠道益生菌，通过脑肠轴体系，调节身体免疫的同时改善疼痛引起的神经问题；其制备方法简单，生产成本低，易操作实施。
为了达到上述目的，本发明采用以下技术方案予以实现。
(一)一种镇痛安神固体饮料，包括以下原料：低聚果糖、芹菜籽提取物、酸枣仁粉、香蜂草、γ-氨基丁酸、低聚甘露糖、复合维生素、姜黄、菊粉、调味剂和稳定剂。
优选的，所述复合维生素包含维生素B1和维生素E。
优选的，所述调味剂包含结晶果糖或/和柠檬粉。
优选的，所述稳定剂为魔芋。
优选的，所述原料的用量为：低聚果糖20-30份、芹菜籽提取物15-25份、酸枣仁粉15-25份、香蜂草8-12份、γ-氨基丁酸0.8-1.2份、低聚甘露糖3-7份、复合维生素2-3份、姜黄0.1-0.3份、菊粉0.8-1.2份、调味剂8-12份，余量为稳定剂。
进一步优选的，所述原料的用量为：低聚果糖25份、芹菜籽提取物20份、酸枣仁粉20份、香蜂草10份、γ-氨基丁酸1份、低聚甘露糖5份、复合维生素2.1份、姜黄0.2份、菊粉1份、调味剂10份，余量为稳定剂。
优选的，所述复合维生素包含维生素B10.1-0.3份和维生素E 1.9-2.7份。
进一步优选的，所述复合维生素包含维生素B10.1份和维生素E 2份。
(二)一种镇痛安神固体饮料的制备方法，包括以下制备步骤：将低聚果糖、芹菜籽提取物、酸枣仁粉、香蜂草、γ-氨基丁酸、低聚甘露糖、复合维生素、姜黄、菊粉、调味剂和稳定剂混合均匀，得镇痛安神固体饮料。
与现有技术相比，本发明的有益效果为：
本发明的镇痛安神固体饮料从三方面辅助改善疼痛，首先是采用芹菜籽提取物、姜黄成分改善炎症疼痛；其次采用酸枣仁粉、香蜂草、γ-氨基丁酸改善因疼痛造成的神经方面(焦虑、抑郁等)问题；最后采用复合益生元(低聚甘露糖、低聚果糖、菊粉)改善肠道益生菌，通过脑肠轴体系，调节身体免疫的同时改善疼痛引起的神经问题。
其中，芹菜籽提取物和姜黄针对的疼痛类型不同，芹菜籽提取物中含有的黄酮类成分(丁基苯酞)对痛风改善明显；姜黄中姜黄素对于降低炎性因子释放，减轻神经病理性疼痛明显。低聚甘露糖、低聚果糖、菊粉这三种益生元对于不同种类益生菌的增长丰度和速度不同，通过合理比例的组合，可以显著改善疼痛引起的神经问题。维生素B1、维生素E与植物提取成分(芹菜籽提取物和姜黄)组合，可以使芹菜籽提取物、姜黄的镇痛抗炎功效作用更好的发挥。
具体实施方式
下面将结合实施例对本发明的实施方案进行详细描述，但是本领域的技术人员将会理解，下列实施例仅用于说明本发明，而不应视为限制本发明的范围。
实施例1
一种镇痛安神固体饮料的制备方法，包括以下制备步骤：将25％低聚果糖、20％芹菜籽提取物、20％酸枣仁粉、10％香蜂草、1％γ-氨基丁酸、5％低聚甘露糖、0.1％维生素B1、2％维生素E、0.2％姜黄、1％菊粉、10％结晶果糖和5.7％魔芋混合均匀，得镇痛安神固体饮料。
实施例2
一种镇痛安神固体饮料的制备方法，包括以下制备步骤：将25％低聚果糖、25％芹菜籽提取物、15.7％酸枣仁粉、8％香蜂草、1.2％γ-氨基丁酸、7％低聚甘露糖、0.3％维生素B1、2.7％维生素E、0.1％姜黄、0.8％菊粉、8％柠檬粉和6.2％魔芋混合均匀，得镇痛安神固体饮料。
实施例3
一种镇痛安神固体饮料的制备方法，包括以下制备步骤：将30％低聚果糖、15％芹菜籽提取物、20％酸枣仁粉、12％香蜂草、0.8％γ-氨基丁酸、3％低聚甘露糖、0.1％维生素B1、1.9％维生素E、0.3％姜黄、1.2％菊粉、12％柠檬粉和3.7％魔芋混合均匀，得镇痛安神固体饮料。
实施例4
一种镇痛安神固体饮料的制备方法，包括以下制备步骤：将30％低聚果糖、15％芹菜籽提取物、25％酸枣仁粉、8％香蜂草、0.8％γ-氨基丁酸、3％低聚甘露糖、0.1％维生素B1、1.9％维生素E、0.3％姜黄、0.8％菊粉、5％柠檬粉、5％结晶果糖和5.1％魔芋混合均匀，得镇痛安神固体饮料。
实施例5
一种镇痛安神固体饮料的制备方法，包括以下制备步骤：将20％低聚果糖、25％芹菜籽提取物、25％酸枣仁粉、8％香蜂草、0.8％γ-氨基丁酸、3％低聚甘露糖、0.1％维生素B1、1.9％维生素E、0.3％姜黄、0.8％菊粉、5％柠檬粉、5％结晶果糖和5.1％魔芋混合均匀，得镇痛安神固体饮料。
实施例6
一种镇痛安神固体饮料的制备方法，包括以下制备步骤：将30％低聚果糖、25％芹菜籽提取物、15％酸枣仁粉、8％香蜂草、0.8％γ-氨基丁酸、3％低聚甘露糖、0.2％维生素B1、2.3％维生素E、0.1％姜黄、0.8％菊粉、5％柠檬粉、5％结晶果糖和4.8％魔芋混合均匀，得镇痛安神固体饮料。
以上实施例中，镇痛安神固体饮料中各原料的作用如下：
芹菜籽提取物：芹菜籽提取物可以减少大鼠现有的炎症，防止和/或减少由NSAID(不含有甾体结构的抗炎药)引起的胃刺激，以及与它们协同作用以减轻炎症。与许多膳食补充剂不同，芹菜籽提取物不会显着影响p450酶系统，因此不太可能改变个体可能服用的药物的代谢，可显著增加和延长氨基比林、乙酰氨基酚的镇静和止痛作用，可以用于治疗关节炎和其他炎性疾病。
酸枣仁粉：酸枣仁粉可改善患者睡眠质量，是治疗失眠症的有效药物，其作用机理为：钙调蛋白作为脑中重要的Ca2+转换系统在神经兴奋性方面有非常重要的控制作用。运用磁共振氢谱和自旋标示电子顺磁共振谱发现，酸枣仁粉中的酸枣仁皂苷A是非竞争性钙调蛋白抑制剂，在钙调蛋白上有两类结合位点，一类位于多肽链的N端，另一类位于多肽链的C端。酸枣仁皂苷A可以通过疏水相互作用与钙调蛋白结合，其结合可影响一些赖氨酸残基的微环境，每个钙调蛋白至少能结合两分子酸枣仁皂苷A。
γ-氨基丁酸：γ-氨基丁酸(GABA)是哺乳动物脑组织中重要的起抑制作用的神经抑制剂。哺乳动物大脑中含量最多的也是最重要的GABA受体是GABAA。因为在中枢神经发育过程中，GABAA在三种受体中出现的最早，且分布最广泛，主要位于海马、前额皮层及纹状体等脑区，所以大多数GABA能突触传递是GABAA介导的。GABA与有扩张血管作用的突触后GABAA受体和对交感神经末梢有抑制作用的GABAb受体相结合，能够促进血管扩张，从而达到降血压的目的。在海马和前额皮层中存在大量的大麻素受体1(CB1受体)，这些受体主要位于GABA神经元轴突末端，CB1受体的激活可以调控海马椎体神经元GABA的释放，由于海马和前额皮层都是和记忆相关的脑区，所以CB1受体通过对GABA的调控从而影响记忆功能。此外，GABA是一种介导抗癫痫、抗焦虑、镇静药物、抗惊厥药物、肌肉迟缓药物和失忆活动的多功能药物作用的重要靶标。
香蜂草：GABA是哺乳动物中枢神经系统中重要的抑制性神经递质，是目前研究镇静、抗焦虑、抗抑郁一个重要靶点。迷迭香酸作为香蜂草有效成分之一，其能够抑制GABA转氨酶，抑制GABA的降解，从而提高脑内的GABA浓度，起到抗焦虑、镇静的作用。此外香蜂草另外两种主要组成成分：咖啡酸、柠檬醛具有抗焦虑的功效。香蜂草的某些有效成分还具有保护神经元的作用，是通过抑制突触间隙的胆碱酯酶活性，增加乙酰胆碱(ACh)活性及含量，从而发挥保护神经系统的功能。香蜂草提取物能够保护亚甲二氧基甲基安非他明诱导的海马初级神经元细胞的凋亡，是通过其较强的抗氧化性和对单胺氧化酶(MAO)的抑制而实现的。
益生元：包括低聚果糖、低聚甘露糖、菊粉等，益生元通过改善肠道益生菌，通过脑肠轴体系，调节身体免疫的同时改善疼痛引起的神经问题。脑肠轴是肠内细菌与大脑间的双向通信系统，其交流途径包括：神经系统、内分泌、免疫以及代谢途径。迷走神经是肠道细菌与大脑间交流的重要途径，迷走神经切除术后，鼠李糖乳杆菌就会大量减少。肠道细菌同样会调节中枢神经传导物质，如调控前体水平来调节血清素。婴儿双歧杆菌提高了血浆色氨酸水平从而影响中枢血清素传导。一些细菌可以合成并分泌神经传导物质，这些物质可以穿过小肠粘膜层，通过肠道神经系统实现的。短链脂肪酸(SCFA)是肠道细菌的代谢产物，包括丁酸盐、丙酸盐和醋酸盐等，可以通过G蛋白偶联受体等对大脑活动起到作用。短链脂肪酸还兼顾能量平衡和代谢功能，调节脂肪组织、肝组织和骨骼肌及其功能。细胞因子也可以作为脑肠轴的桥梁，细胞因子可以通过释放信号影响大脑，比如BBB缺陷的下丘脑，通过之后的细胞因子白介素(IL)-1和IL-6激活下丘脑-垂体轴，释放皮质醇，这是压力系统中最有效的激活剂。
低聚果糖：又称蔗果低聚糖，是由1～3个果糖基通过β(2-1)糖苷键与蔗糖中的果糖基结合生成的蔗果三糖、蔗果四糖和蔗果五糖等的混合物。β2-1果聚糖是具有益生元特性的碳水化合物分子，通过抵抗上胃肠道中的消化，并完整地到达结肠，然后选择性地刺激肠道微生物群的有益成员的生长和/或活动。通过肠道微生物群的这种修饰，以及通过其他机制，β2-1果聚糖可以对免疫功能，对抗感染的能力以及炎症过程和条件具有有益作用。肠道和全身免疫系统的先天性和适应性免疫的某些方面被β2-1果聚糖修饰。β2-1果聚糖能够调节免疫功能的某些方面，提高宿主成功应对某些肠道感染的能力，并改变一些炎症状况。
姜黄：姜黄素是从姜科植物姜黄的根茎中提取的一种橙黄色多酚类物质，具有抗肿瘤、抗病毒、抗风湿、抗氧化、抗炎症反应的药理特性，可以改善癌症、炎症、糖尿病、心血管疾病及神经系统疾病等多种疾病症状。姜黄素对多种疼痛均具有良好的效果，如外周神经损伤所致的神经病理性疼痛、糖尿病周围神经痛、手术后疼痛和炎症性疼痛等。
复合维生素：维生素B1、维生素E与植物提取成分(芹菜籽提取物、姜黄)组合，可以使芹菜籽提取物、姜黄的镇痛抗炎功效作用更好的发挥。
魔芋：属于膳食纤维，作为一种稳定剂，对固体饮料的溶液起到增稠稳定溶液的体系的作用。
结晶果糖：作为一种甜味剂，可以改善芹菜籽提取物等中的苦涩味，用于调节镇痛安神固体饮料的口感，使其口感更佳，满足消费者的口感需求。
对镇痛安神固体饮料中各原料的感官指标、理化指标进行检测，具体检测结果分别如表1-4所示。
表1低聚果糖的检测结果
表2低聚甘露糖的检测结果
表3菊粉的检测结果
表4香蜂草的检测结果
由表1-4可知，本发明的镇痛安神固体饮料中的低聚果糖、低聚甘露糖、菊粉、香蜂草等原料的感官指标、理化指标和微生物指标等均符合标准要求，原料性质稳定，利用其制备的镇痛安神固体饮料的性质稳定，更加安全可靠。
本发明所得的产品的食用方法为：20g的镇痛安神固体饮料为一包，每天一包，饮用时每包中加入150-200mL的水冲饮即可。将以上实施例所得的镇痛安神固体饮料用于疼痛、失眠和抑郁等健康问题的人群进行临床观察，结果表明，本发明所得的镇痛安神固体饮料对疼痛、失眠人群有效率达90％以上；其中，对100例疼痛人群有效率达90％以上；对100例因疼痛引起的失眠、抑郁的人群的有效率达92％以上，以下为发明本镇痛安神固体饮料的部分典型病例的临床效果：
1、慢性炎症疼痛：
症状：头痛、牙痛、关节炎性疼痛、痛风等。
病例1
张先生，44岁，患者偏头痛8年，发作不定时，1个月发作两三次。发作无规律，疼痛部位多在左额颞侧，呈剧烈的跳痛或刺痛，遇风则痛剧，平时疼痛尚可忍受，痛剧时头痛欲裂，眼胀、耳鸣、呕吐、烦躁不安、彻夜难眠。近年来遗忘明显，影响正常工作。经服用实施例1所得的镇痛安神固体饮料2天即感有效，7天后，头痛明显减轻，坚持服用1月，头痛及伴随症状疾病消失，自觉精力充沛，已能工作。
病例2
李女士，43岁，患者因长期关节炎症疼痛，心情抑郁，近2个月来脘胁胀痛，腹胀便溏，夜不能寐，伴倦怠疲乏，纳少，口干而不喜饮，舌质淡，苔薄白，脉弦细。经服用实施例2所得的镇痛安神固体饮料5天即感有效，10天后，疼痛明显减轻，睡眠质量稍好，坚持服用1月，疼痛及伴随症状疾病消失，睡眠佳，精力好。
2、疼痛引起的失眠、抑郁
症状：失眠、抑郁等精神性问题。
病例1
刘女士，32岁，因精神受刺激，整日情志抑郁，善悲欲哭，心烦不眠，恶梦连连3月余，近日病情加重，昼夜徘徊唠叨，时而吵闹不宁，表情淡漠，舌红少津，脉弦细。经服用实施例1所得的镇痛安神固体饮料3天，症状大减，持续服用14天，痊愈。
病例2
刘女士，38岁，患者4年前因经常熬夜工作以致精神过度紧张而失眠，每晚只能睡1～3小时，多普勒及头颅CT检查均未见异常。月前因岗位调换不如意而心情不畅，彻夜不眠，梦多，记忆力减退。西医诊为“神经衰弱”，用镇静剂及中药安神剂治疗，效果不佳。经服用实施例3所得的镇痛安神固体饮料7天，睡眠恢复正常，每晚能睡6～7小时，持续服用14天，诸症悉除。
虽然，本说明书中已经用一般性说明及具体实施方案对本发明作了详尽的描述，但在本发明基础上，可以对之作一些修改或改进，这对本领域技术人员而言是显而易见的。因此，在不偏离本发明精神的基础上所做的这些修改或改进，均属于本发明要求保护的范围。
Claims (9)
1.一种镇痛安神固体饮料，其特征在于，包括以下原料：低聚果糖、芹菜籽提取物、酸枣仁粉、香蜂草、γ-氨基丁酸、低聚甘露糖、复合维生素、姜黄、菊粉、调味剂和稳定剂。
2.根据权利要求1所述的镇痛安神固体饮料，其特征在于，所述复合维生素包含维生素B1和维生素E。
3.根据权利要求1所述的镇痛安神固体饮料，其特征在于，所述调味剂包含结晶果糖或/和柠檬粉。
4.根据权利要求1所述的镇痛安神固体饮料，其特征在于，所述稳定剂为魔芋。
5.根据权利要求2所述的镇痛安神固体饮料，其特征在于，所述原料的用量为：低聚果糖20-30份、芹菜籽提取物15-25份、酸枣仁粉15-25份、香蜂草8-12份、γ-氨基丁酸0.8-1.2份、低聚甘露糖3-7份、复合维生素2-3份、姜黄0.1-0.3份、菊粉0.8-1.2份、调味剂8-12份，余量为稳定剂。
6.根据权利要求5所述的镇痛安神固体饮料，其特征在于，所述原料的用量为：低聚果糖25份、芹菜籽提取物20份、酸枣仁粉20份、香蜂草10份、γ-氨基丁酸1份、低聚甘露糖5份、复合维生素2.1份、姜黄0.2份、菊粉1份、调味剂10份，余量为稳定剂。
7.根据权利要求5所述的镇痛安神固体饮料，其特征在于，所述复合维生素包含维生素B10.1-0.3份和维生素E 1.9-2.7份。
8.根据权利要求7所述的镇痛安神固体饮料，其特征在于，所述复合维生素包含维生素B1 0.1份和维生素E 2份。
9.一种镇痛安神固体饮料的制备方法，其特征在于，包括以下制备步骤：将低聚果糖、芹菜籽提取物、酸枣仁粉、香蜂草、γ-氨基丁酸、低聚甘露糖、复合维生素、姜黄、菊粉、调味剂和稳定剂混合均匀，得镇痛安神固体饮料。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811115455.2A CN109198353A (zh) | 2018-09-25 | 2018-09-25 | 一种镇痛安神固体饮料及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811115455.2A CN109198353A (zh) | 2018-09-25 | 2018-09-25 | 一种镇痛安神固体饮料及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109198353A true CN109198353A (zh) | 2019-01-15 |
Family
ID=64984794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811115455.2A Pending CN109198353A (zh) | 2018-09-25 | 2018-09-25 | 一种镇痛安神固体饮料及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109198353A (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110959795A (zh) * | 2019-12-25 | 2020-04-07 | 河南佳禾康生物食品科技有限公司 | 一种γ-氨基丁酸固体饮料及其制备方法 |
| CN116076715A (zh) * | 2022-12-12 | 2023-05-09 | 福州三合元生物科技有限公司 | 一种抑炎的伽马氨基丁酸制剂及其制备方法 |
| CN116114875A (zh) * | 2023-01-19 | 2023-05-16 | 宁波御坊堂生物科技有限公司 | 一种基于肠-脑轴的植物基组合物及其制备方法 |
| CN116114875B (zh) * | 2023-01-19 | 2024-05-31 | 宁波御坊堂生物科技有限公司 | 一种基于肠-脑轴的植物基组合物及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102038248A (zh) * | 2010-11-01 | 2011-05-04 | 华润怡宝食品饮料（深圳）有限公司 | 一种舒缓饮料 |
| CN105341947A (zh) * | 2015-10-27 | 2016-02-24 | 江西美庐乳业集团有限公司 | 一种改善睡眠的营养包 |
| CN107737331A (zh) * | 2017-11-20 | 2018-02-27 | 中食都庆（山东）生物技术有限公司 | 一种具有镇静安神作用的复方产品及其制备方法 |
-
2018
- 2018-09-25 CN CN201811115455.2A patent/CN109198353A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102038248A (zh) * | 2010-11-01 | 2011-05-04 | 华润怡宝食品饮料（深圳）有限公司 | 一种舒缓饮料 |
| CN105341947A (zh) * | 2015-10-27 | 2016-02-24 | 江西美庐乳业集团有限公司 | 一种改善睡眠的营养包 |
| CN107737331A (zh) * | 2017-11-20 | 2018-02-27 | 中食都庆（山东）生物技术有限公司 | 一种具有镇静安神作用的复方产品及其制备方法 |
Non-Patent Citations (4)
| Title |
|---|
| （美）加利•纽尔（GARY NULL）著: "《加利•纽尔家庭健康宝典》", 31 October 2001, 海南出版社 * |
| （美）穆拉德等: "《神奇的一氧化氮》", 31 October 2011, 译林出版社 * |
| 三采文化编著: "《芳香药草养生事典》", 31 July 2005, 汕头大学出版社 * |
| 李波等: "肠道菌群-肠-脑轴与心身疾病的相互关系", 《生理科学进展》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110959795A (zh) * | 2019-12-25 | 2020-04-07 | 河南佳禾康生物食品科技有限公司 | 一种γ-氨基丁酸固体饮料及其制备方法 |
| CN116076715A (zh) * | 2022-12-12 | 2023-05-09 | 福州三合元生物科技有限公司 | 一种抑炎的伽马氨基丁酸制剂及其制备方法 |
| CN116114875A (zh) * | 2023-01-19 | 2023-05-16 | 宁波御坊堂生物科技有限公司 | 一种基于肠-脑轴的植物基组合物及其制备方法 |
| CN116114875B (zh) * | 2023-01-19 | 2024-05-31 | 宁波御坊堂生物科技有限公司 | 一种基于肠-脑轴的植物基组合物及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CV et al. | Herbal approach for obesity management | |
| Mohamed et al. | Natural anti-obesity agents | |
| JP6077305B2 (ja) | アミノ酸および植物を含む調製物およびアルコール解毒におけるその活性 | |
| JP5204771B2 (ja) | Ｇａｂａ作動性ニューロン賦活剤 | |
| CN103609944A (zh) | 降血压助眠的保健食品 | |
| CN109745359A (zh) | 有利于保持血糖平衡和预防糖尿病及其并发症的组合物及其制备方法 | |
| CN103156108B (zh) | 一种防治糖尿病高血压病症的强化食品 | |
| CN102302149A (zh) | 多参保健食品及其制备方法 | |
| CN114271502A (zh) | 一种保护心血管系统和肾脏的蛤蜊肽复合物及其应用 | |
| Banga et al. | Nutraceutical potential of diet drinks: a critical review on components, health effects, and consumer safety | |
| CN109198353A (zh) | 一种镇痛安神固体饮料及其制备方法 | |
| Sharma et al. | Revisiting Licorice as a functional food in the management of neurological disorders: bench to trend | |
| CN103445175B (zh) | 具有解酒保肝作用的组合物 | |
| KR101466443B1 (ko) | 혼합 생약 추출물을 유효성분으로 포함하는 항암용 조성물 | |
| Yuan et al. | The effects of Sea buckthorn seed protein on glucose metabolism in streptozotocin-induced diabetic ICR mice. | |
| KR101951402B1 (ko) | 뇌 신경세포 보호 활성을 갖는 사군자탕 유산균 발효물 및 이의 용도 | |
| CN103006709A (zh) | 防治酒精性脂肪肝的蜂花粉合剂口含片 | |
| CN107787191B (zh) | 包含饮料和珠粒的用于减重的组合物 | |
| US9445624B2 (en) | Anti-fatigue composition of plant material and preparation method, use and products thereof | |
| Jung et al. | Weight reduction effects of yeast hydrolysate below 10 kDa on obese young women | |
| Saad et al. | Anti-obesity medicinal plants | |
| CN111869876A (zh) | 一种解酒护肝保健品及其制备方法 | |
| KR20130090936A (ko) | 해당화 추출물을 유효성분으로 함유하는 수면부족으로 인한 스트레스 관련 질환의 치료 및 예방을 위한 조성물 | |
| CN108272845A (zh) | 一种抗抑郁复方制剂 | |
| Boix-Castejón et al. | Plant compounds for obesity treatment through neuroendocrine regulation of hunger: A systematic review |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190115 |
|
| RJ01 | Rejection of invention patent application after publication |